Loading...

Lindsay A. Renfro, PhD

Title(s)Associate Professor of Research Preventive Medicine
Phone+1 507 535 9755
ORCID ORCID Icon0000-0002-4306-1896 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Texas Woman's UniversityB.S.05/2005Mathematics
    Rice UniversityPh.D. Student05/2006Statistics
    Baylor UniversityM.S.12/2007Statistics
    Baylor UniversityPh.D.03/2011Statistics
    Collapse Awards and Honors
    Texas Woman's University2018Hallmark Alumni Award
    Mayo Clinic2015  - 2018KL2 Mentored Career Development Award
    ENAR / International Biometric Society2011Distinguished Student Paper Award
    Baylor University2006  - 2011Dean's Stipend Enhancement Award
    National Science Foundation, National Center for Education Statistics2010Fellow, National Summer Data Policy Institute
    Association for Institutional Research, National Center for Education Statistics2008  - 2010AIR/NCES Graduate Fellowship
    Association for Institutional Research2007Best Paper Award
    Kappa Mu Epsilon National Mathematics Honor Society2005Best Paper Award
    Texas Woman's University2005Chancellor's Research Scholar
    Texas Woman's University2004  - 2005Harlan Miller Award and Memorial Scholarship
    Texas Instruments2003  - 2005Women in Engineering Award and Scholarship

    Collapse Overview 
    Collapse Overview
    Dr. Lindsay Renfro is an Associate Professor of Research at the University of Southern California and the Associate Group Statistician for Children's Oncology Group (COG). COG is the pediatric cooperative group member of the NIH/NCI's National Clinical Trials Network and the world's largest organization dedicated exclusively to pediatric cancer research. Within COG, Dr. Renfro is also a faculty statistician for the Renal Tumors Committee, where she leads the design and analysis of therapeutic and biology-driven clinical trials for Wilms Tumor and related projects in pediatric renal cancer. Her expertise and methodological interests also include novel trial designs (e.g., adaptive, Bayesian, biomarker-driven, and master protocols), evaluation and validation of surrogate endpoints in clinical trials, and construction, validation, and implementation of disease-specific prognostic calculators for clinical use and decision-making. Dr. Renfro also enjoys teaching statistics to non-statisticians, mentoring students, traveling, and enjoying the mountains and beaches of Southern California with her son, Will.

    Collapse Research 
    Collapse Research Activities and Funding
    Children's Oncology Group Statistics and Data Center
    NIH U10CA180899Apr 15, 2014 - Feb 28, 2025
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection. Stat Med. 2020 Aug 30; 39(19):2568-2586. Kimani PK, Todd S, Renfro LA, Glimm E, Khan JN, Kairalla JA, Stallard N. PMID: 32363603.
      View in: PubMed   Mentions:    Fields:    
    2. Reply to D.M. Green. J Clin Oncol. 2020 03 01; 38(7):773-774. Dix DB, Fernandez CV, Chi YY, Renfro LA, Md JSD. PMID: 31951494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group. JCO Precis Oncol. 2019; 3. Renfro LA, Ji L, Piao J, Onar-Thomas A, Kairalla JA, Alonzo TA. PMID: 32923863.
      View in: PubMed   Mentions:
    4. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30(7):757-765. Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. PMID: 31104167.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Ann Oncol. 2019 04 01; 30(4):506-509. Stallard N, Todd S, Parashar D, Kimani PK, Renfro LA. PMID: 30715156.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018 11; 103:205-213. Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. PMID: 30268921.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018 06 01; 110(6):638-648. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR. PMID: 29267900.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    8. Point estimation following two-stage adaptive threshold enrichment clinical trials. Stat Med. 2018 09 30; 37(22):3179-3196. Kimani PK, Todd S, Renfro LA, Stallard N. PMID: 29855066.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018 Mar 29; 378(13):1177-1188. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. PMID: 29590544.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    10. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res. 2018 01 15; 24(2):316-325. Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA. PMID: 29084918.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    11. Definitions and statistical properties of master protocols for personalized medicine in oncology. J Biopharm Stat. 2018; 28(2):217-228. PMID: 28877008.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2624-2630. PMID: 28486044.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    13. Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision. Dis Colon Rectum. 2017 May; 60(5):459-468. PMID: 28383445.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2017 Jun 10; 35(17):1929-1937. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ. PMID: 28414610.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    15. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017 01 01; 28(1):34-43. PMID: 28177494.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    16. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Chin Clin Oncol. 2016 Dec; 5(6):80. PMID: 28061544.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. J Clin Oncol. 2016 11 10; 34(32):3949-3950. PMID: 27551133.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer. Clin Colorectal Cancer. 2017 03; 16(1):23-30. PMID: 27600983.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J Geriatr Oncol. 2016 11; 7(6):422-429. PMID: 27468630.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Precision oncology: A new era of cancer clinical trials. Cancer Lett. 2017 02 28; 387:121-126. PMID: 26987624.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    21. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10; 34(11):1182-9. PMID: 26858337.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016 Mar 10; 34(8):843-53. PMID: 26811529.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    23. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev. 2016 Feb; 43:74-82. PMID: 26827695.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    24. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10; 34(2):144-50. PMID: 26503203.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    25. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015 Nov; 16(15):1537-1546. PMID: 26474521.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    26. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    27. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. Ann Oncol. 2015 May; 26(5):950-958. PMID: 25697217.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. J Biopharm Stat. 2015; 25(4):857-77. PMID: 24905465.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaboration. Forum Clin Oncol. 2014 Dec; 5(2):1-7. PMID: 26989447.
      View in: PubMed   Mentions:
    30. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014 Dec; 32(12):1231-43. PMID: 25154747.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106(12). PMID: 25359867.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    32. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One. 2014; 9(10):e108483. PMID: 25310185.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    33. Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. Comput Stat Data Anal. 2014 Oct 01; 78:1-20. PMID: 25061255.
      View in: PubMed   Mentions:
    34. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84. PMID: 25002720.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    35. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45. PMID: 24859205.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    36. Genetic markers of treatment response to tumour necrosis factor-a inhibitors in the treatment of psoriasis. Clin Exp Dermatol. 2014 Jun; 39(4):519-24. PMID: 24758522.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. PLoS One. 2014; 9(4):e94727. PMID: 24727911.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014 May; 19(5):492-7. PMID: 24710310.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    39. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar 01; 3(1). PMID: 25485277.
      View in: PubMed   Mentions: 3     Fields:    
    40. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar; 3(1):3. PMID: 25842081.
      View in: PubMed   Mentions: 1     Fields:    
    41. Mining the ACCENT database: a review and update. Chin Clin Oncol. 2013 Jun; 2(2):18. PMID: 25841498.
      View in: PubMed   Mentions: 3     Fields:    
    42. Chronic consequences of acute injuries: worse survival after discharge. J Trauma Acute Care Surg. 2012 Sep; 73(3):699-703. PMID: 22710768.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. Stat Med. 2012 Apr 13; 31(8):743-61. PMID: 22161275.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    44. Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics. 2012 Mar; 68(1):258-67. PMID: 21838811.
      View in: PubMed   Mentions: 3     Fields:    
    45. Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. Br J Dermatol. 2010 Nov; 163(5):1056-63. Ryan C, Renfro L, Collins P, Kirby B, Rogers S. PMID: 20716226.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol. 1993 Feb; 129(2):182-8. Renfro L, Geronemus RG. PMID: 8434975.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    47. Ulcerative lichen planus-like dermatitis associated with hydroxyurea. J Am Acad Dermatol. 1991 Jan; 24(1):143-5. Renfro L, Kamino H, Raphael B, Moy J, Sanchez M. PMID: 1825667.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Lindsay's Networks
    Concepts (189)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑